Clinical trials: Healthy Volunteers Only
- Condition Healthy Volunteers Only
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Healthy Volunteers
Phase 1, TAK-648, Single-Rising Dose Study
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of TAK-648 when administered as a single oral dose of TAK-648 solution at escalating dose levels in healthy participants.
- Trial name
- NCT02684396
- Testing
- TAK-648
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy
BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants
The primary objective of this study is to investigate the safety and tolerability of BGB-DXP604 alone and in combination with BGB-DXP593 in healthy participants
- Trial name
- NCT04669262
- Testing
- BGB-DXP604, BGB-DXP593
- Where
- Australia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- BeiGene
Healthy Volunteer
A Study of the Effects of Posaconazole on Alectinib (RO5424802) Pharmacokinetics in Healthy Volunteers
This open-label study will investigate whether multiple oral doses of posaconazole affect the single dose pharmacokinetics of alectinib in healthy volunteers.
- Trial name
- NCT01984229
- Testing
- Alectinib, Posaconazole
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy Participants
A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy Adults
A phase I, single dose study to test two forms of pediatric ritlecitinib compared to adult ritlecitinib in healthy adults aged 18-55 years old. Approximately 12 adults will participate for approximately 2.5 months.
- Trial name
- NCT05040295
- Testing
- ritlecitinib
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Single Dose Safety, Tolerance and Pharmacokinetic Study in Healthy Volunteers Undergoing Contrast-enhanced Abdominal Computed Tomography (CT)
This is a non-randomized dose-escalating study that will evaluate the safety and tolerability of GE-145 at four different dose levels through the assessment of clinical laboratories, vital signs, physical examinations…
- Trial name
- NCT01004770
- Testing
- GE-145 (AN113111) Injection, Visipaque (iodixanol) Injection
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Healthy Volunteers
To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects
The purpose of this study is to compare the pharmacokinetics, as well as to evaluate the safety, tolerability and immunogenicity of HD204, US-Avastin and EU-Avastin in healthy male subjects after intravenous administration of a…
- Trial name
- NCT03390673
- Testing
- HD204, Avastin
- Where
- 2 sites in New Zealand
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Prestige Biopharma Limited
Pain
Bioequivalence Study for Mejoral 500 Product
This will be a monocentric, single blinded, randomized, single-dose, two-periods, two-sequence, crossover bioequivalence study of two oral formulations in healthy participants under fasting conditions.
- Trial name
- NCT02504775
- Testing
- Mejoral® 500 Tablets, Tylenol® Caplets
- Where
- Mexico
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Volunteers, Healthy
A Study to Evaluate Plasma Gelsolin in Healthy Volunteers
Study BTI-101 is a Phase 1, randomized, double-blind, placebo-controlled, dose escalation, parallel design study to evaluate the safety, tolerability, and pharmacokinetics of IV rhu-pGSN or saline placebo administered as 5 doses…
- Trial name
- NCT05789745
- Testing
- Recombinant human plasma gelsolin
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- BioAegis Therapeutics Inc.
Healthy
Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants
This study investigated the bioequivalence and drug-drug interaction of Metformin/Gliclazide fixed combination tablet compared to co-administration of individual tablets of Metformin and Gliclazide.
- Trial name
- NCT03467945
- Testing
- Metformin/Gliclazide Fixed Combination, Metformin, Gliclazide
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merck KGaA, Darmstadt, Germany
Healthy Volunteers
A Study of Insulin Peglispro in Healthy Male Japanese Participants
The main purpose of this study is to evaluate how the body processes the study drug known as insulin peglispro and how the study drug affects blood sugar in healthy male Japanese participants.
- Trial name
- NCT01995526
- Testing
- Insulin Peglispro
- Where
- Japan
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Urticaria
Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264
This First Time in Human (FTIH) study, which will be performed in three parts, is designed to investigate the safety, local tolerability, pharmacokinetics and pharmacodynamics after single and repeat topical applications of up to…
- Trial name
- NCT02424799
- Testing
- GSK2646264 0.5% topical cream, GSK2646264 1% topical cream
- Where
- 6 sites in Germany, United Kingdom
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Drug-Drug Interaction, Heathy Volunteer
Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity
Primary objective: 1. To assess the potential inhibitory and inducing effect of oral givinostat on the single dose pharmacokinetics (PK) of intravenous or oral midazolam. 2.
- Trial name
- NCT05492318
- Testing
- Givinostat 10 mg/mL, Midazolam 1mg/ml IV, Midazolam 2.5 mg oromucosal solution
- Where
- Portugal
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Italfarmaco
Healthy
A Study of Glucagon Administered in Different Forms and Routes to Healthy Adults
The main purpose of this study was to evaluate the safety and tolerability of nasal glucagon (NG). The study drug was delivered into the participant's nostril (intranasally) or was given as an injection just under the skin…
- Trial name
- NCT02778113
- Testing
- Nasal Glucagon, Glucagon
- Where
- Canada
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteers
Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers
This will be a randomized, single dose, open-label, three-treatment period crossover study in healthy participants to determine whether 2 test lots of 10-mg capsules that vary by the level of lenvatinib Type-C crystal are…
- Trial name
- NCT02723630
- Testing
- Lenvatinib 10 mg
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Autoimmune Diseases
A Study of the Safety, Tolerability, Pharmacokinetics and Food Effect After Single and Multiple Ascending Oral Doses
This is a Phase I Healthy volunteer study with the primary objective to evaluate the safety and pharmacokinetics profile of AX-158. The first part will evaluate single ascending dose administrations.
- Trial name
- NCT05218434
- Testing
- AX-158
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Artax Biopharma Inc
Schizophrenia
A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.
This is a prospective, 8-day, randomized, double-blind, placebo-controlled, sequential-cohort study designed to evaluate the safety, tolerability, and MTD of single escalating oral doses of NW-3509A in healthy male volunteers.
- Trial name
- NCT01955564
- Testing
- NW-3509a
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Newron Pharmaceuticals SPA
Healthy
A Study of LY2409021 Formulations in Healthy Participants
The purpose of this study is to measure how much of the new LY2409021 tablet formulations get into the blood stream and how long it takes the body to get rid of them, compared to the current LY2409021 capsule formulation.
- Trial name
- NCT02385084
- Testing
- LY2409021
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Muscular Atrophy, Spinal
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic Function
This is a multi-center, open-label, non-randomized, parallel-group, 2-part study to evaluate the effect of hepatic impairment on the PK and safety and tolerability of a single oral dose of risdiplam compared to matched healthy…
- Trial name
- NCT03920865
- Testing
- Risdiplam
- Where
- 3 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy
600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions
The objective of this study is to assess the bioequivalence between Amoxicillin and Clavulanate Potassium for Oral Suspension, 600/42.9 mg/5 mL and Augmentin ES-600™ for Oral Suspension, 600/42.9 mg/5 mL in healthy, male and…
- Trial name
- NCT00840099
- Testing
- 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL, Augmentin ES-600™ 600 mg/42.9 mg/5 mL Suspension
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Healthy Volunteers
Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy Subjects
The purpose of this study is to evaluate the safety of a single dose of PT003 compared with single doses of PT001 and PT005, and compared with PT001 plus PT005 delivered together as two separate single doses in healthy subjects.
- Trial name
- NCT00893971
- Testing
- PT001, PT005, PT003
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pearl Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.